Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 16

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 16
---
 and an immediate dilution of $5.66 per share to new investors in this offering. Dilution per share to new investors is determined by subtracting as-adjusted net tangible book value per share after giving effect to this offering from the public offering price per share paid by new investors. The following table illustrates this dilution on a per share basis.

| ​ | Public offering price per share                                                                                        | ​ | ​ | ​ | ​ |    ​ | ​ | ​ | ​ | ​ | $ | 9.23 | ​ | ​ |
| ​ | Net tangible book value per share as of June 30, 2025                                                                  | ​ | ​ | ​ | $ | 0.51 | ​ | ​ | ​ | ​ | ​ |    ​ | ​ | ​ |
| ​ | Increase in net tangible book value per share attributable to the offering and the concurrent private placement        | ​ | ​ | ​ | ​ |    ​ | ​ | ​ | ​ | ​ | ​ | 3.06 | ​ | ​ |
| ​ | As adjusted net tangible book value per share after giving effect to the offering and the concurrent private placement | ​ | ​ | ​ | ​ |    ​ | ​ | ​ | ​ | ​ | ​ | 3.57 | ​ | ​ |
| ​ | Dilution per share to new investors participating in the offering                                                      | ​ | ​ | ​ | ​ |    ​ | ​ | ​ | ​ | ​ | $ | 5.66 | ​ | ​ |

If the underwriters exercise their option to purchase 2,843,987 additional shares in full at the public offering price of $9.23 per share, the as adjusted net tangible book value will increase to $3.81 per share, representing an immediate increase to existing stockholders of $3.30 per share and an immediate dilution of $5.42 per share to new investors. The number of shares of our common stock to be outstanding immediately after this offering is based on 35,987,306 shares of our Class A common stock and no shares of our Class B common stock outstanding as of June 30, 2025 and excludes: • 8,405,371 shares of Class A common stock issuable upon exercise of stock options outstanding under our equity incentive plans as of June 30, 2025 at a weighted average exercise price of $3.78 per share; • 937,983 shares of Class A common stock reserved for future issuance under our